Estimating vaccine efficacy using auxiliary outcome data and a small validation sample.
In vaccine studies, a specific diagnosis of a suspected case by culture or serology of the infectious agent is expensive and difficult. Implementing validation sets in the study is less expensive and is easier to carry out. In studies using validation sets, the non-specific or auxiliary outcome is measured on each participant while the specific outcome is measured only for a small proportion of the participants. Vaccine efficacy, defined as one minus some measure of relative risk, could be severely attenuated if based only on the auxiliary outcome. Applying missing data analysis techniques could thus correct the bias while maintaining statistical efficiency. However, when the sample size in the validation sets is small and the vaccine is highly efficacious, all specific outcomes are likely to be negative in the validation set in the vaccinated group. Two commonly used missing data analysis methods, the mean score method and multiple imputation, depend on the ad hoc continuity correction when none of the specific outcomes are positive and the normality or log-normality assumption of relative risk, which may not hold when the relative risk is highly skewed, to estimate the confidence interval. In this paper, we propose a Bayesian method to estimate vaccine efficacy and its highest probability density (HPD) credible set using Monte Carlo (MC) methods when using auxiliary outcome data and a small validation sample. Comparing the performance of these approaches using data from a field study of influenza vaccine and simulations, we recommend to use the Bayesian method in this situation.
Department of Biostatistics, Rollins School of Public Health, Emory University, 1518 Clifton Road NE, Atlanta, GA 30322, USA. hchu@jhsph.edu
Haitao
H
Chu
M Elizabeth
ME
Halloran
D000293:Adolescent; D001499:Bayes Theorem; D002648:Child; D002675:Child, Preschool; D003198:Computer Simulation; D006801:Humans; D007223:Infant; D007252:Influenza Vaccines / Q000592:standards / Q000627:therapeutic use*; D007251:Influenza, Human / Q000517:prevention & control*; D018448:Models, Immunological; D009010:Monte Carlo Method; D016896:Treatment Outcome
D007252:Influenza Vaccines